投资快报 3

blackangel

我是男的=.=没事。。。也是你教我开了新加坡cimb户口同一个agent

葉芬

我是男的=.=没事。。。也是你教我开了新加坡cimb户口同一个agent
blackangel 发表于 23-2-2011 11:34 PM

哦 抱歉小弟，我還以為有Angel名字的都是小妹。。。




+++++++++++++++


祝： 投資愉快。。。

blue_angel_007

哈哈....又有多一个天使来国际国际区了....欢迎....

victan

回复 3616# 葉芬


    设了止损价，跌破42。就丢票。

blue_angel_007

哦 抱歉小弟，我還以為有Angel名字的都是小妹。。。




+++++++++++++++


祝： 投資愉 ...
葉芬 发表于 23-2-2011 11:42 PM

我也是小弟.........

葉芬

回复  葉芬


    设了止损价，跌破42。就丢票。
victan 发表于 23-2-2011 11:43 PM

玩投機懂得止損就好。

葉芬

我也是小弟.........
blue_angel_007 发表于 23-2-2011 11:43 PM

      不好意思，Blue也是小弟。。。我還以為是小妹呢。。

imaboy

芬姐对TLR有研究吗?

葉芬

芬姐对TLR有研究吗?
imaboy 发表于 23-2-2011 11:50 PM

並沒有真正研究過。
不過曾投機過這支股。

葉芬

SSN Last Done 2.85.

看今晚的1分鐘走勢圖，SSN像是蓄勢待發。



++++++++++++++++++++++++



來了。。。。。

gen_sen

apcvz完全变废纸了?

L.A.LEONG

美股会来10%调整吗？ 关键时刻。

葉芬

美股会来10%调整吗？ 关键时刻。
L.A.LEONG 发表于 24-2-2011 02:43 AM

整體已經是在調整著了。


P/s: 部分的油股倖免。

blue_angel_007

美股两天里跌了近300点。。。看图表还会在下。。。。。

bennywt

每個人都有用油啊。我也有用著。。

呵呵 魚與熊掌不能兼得。。

要SSN股價高 還是 油價高？
葉芬 发表于 23-2-2011 10:24 PM

我希望他的 oil production增加，那么这才能稳定他的价格。

SUNNY仔

昨晚投机AIB 2290,排$3.05睡觉了....三点多时起来看到价钱$3.2..要卖掉时股票行的系统发生问题....搞了整15分钟还是以失败而告终...结果,要拖多一天了...

victan

回复 3632# gen_sen


   

Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K for APP Pharmaceuticals, Inc. (APP)

Contingent Value Rights Issued in September 2008 Will Expire Without Value SCHAUMBURG, Ill., Feb 23, 2011 (BUSINESS WIRE) -- Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) today filed its Form 10-K for APP which provides an update on the Contingent Value Rights (CVRs) granted to APP stockholders in September 2008 in conjunction with Fresenius Kabi Pharmaceuticals Holding's acquisition of APP. Pursuant to the agreement governing the CVRs, the right to receive a payment with respect to the CVRs was contingent upon APP achieving consolidated cumulative Adjusted EBITDA in excess of $1.268 billion for the measurement period (three years ending December 31, 2010). The consolidated Adjusted EBITDA for the measurement period was $1.126 billion. Since the cumulative Adjusted EBITDA did not exceed the required threshold, CVR holders will not receive any payments on the CVRs and the CVRs will expire without value. The company will give formal notice to the NASDAQ Capital Market of its intention to deregister under the Securities Exchange Act of 1934 (the "Exchange Act") and delist the CVRs from the NASDAQ. The Company will also terminate its obligation to file periodic reports, such as a Form 10-K, Form 10-Q or Form 8-K, under the Exchange Act. It is expected that the CVRs will cease trading on NASDAQ on March 4, 2011. The delisting is expected to be made effective by the NASDAQ prior to the end of the first quarter 2011.

Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K for APP Pharmaceuticals, Inc. (APP)

Contingent Value Rights Issued in September 2008 Will Expire Without Value SCHAUMBURG, Ill., Feb 23, 2011 (BUSINESS WIRE) -- Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) today filed its Form 10-K for APP which provides an update on the Contingent Value Rights (CVRs) granted to APP stockholders in September 2008 in conjunction with Fresenius Kabi Pharmaceuticals Holding's acquisition of APP. Pursuant to the agreement governing the CVRs, the right to receive a payment with respect to the CVRs was contingent upon APP achieving consolidated cumulative Adjusted EBITDA in excess of $1.268 billion for the measurement period (three years ending December 31, 2010). The consolidated Adjusted EBITDA for the measurement period was $1.126 billion. Since the cumulative Adjusted EBITDA did not exceed the required threshold, CVR holders will not receive any payments on the CVRs and the CVRs will expire without value. The company will give formal notice to the NASDAQ Capital Market of its intention to deregister under the Securities Exchange Act of 1934 (the "Exchange Act") and delist the CVRs from the NASDAQ. The Company will also terminate its obligation to file periodic reports, such as a Form 10-K, Form 10-Q or Form 8-K, under the Exchange Act. It is expected that the CVRs will cease trading on NASDAQ on March 4, 2011. The delisting is expected to be made effective by the NASDAQ prior to the end of the first quarter 2011.

Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K for APP Pharmaceuticals, Inc. (APP)

Contingent Value Rights Issued in September 2008 Will Expire Without Value SCHAUMBURG, Ill., Feb 23, 2011 (BUSINESS WIRE) -- Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) today filed its Form 10-K for APP which provides an update on the Contingent Value Rights (CVRs) granted to APP stockholders in September 2008 in conjunction with Fresenius Kabi Pharmaceuticals Holding's acquisition of APP. Pursuant to the agreement governing the CVRs, the right to receive a payment with respect to the CVRs was contingent upon APP achieving consolidated cumulative Adjusted EBITDA in excess of $1.268 billion for the measurement period (three years ending December 31, 2010). The consolidated Adjusted EBITDA for the measurement period was $1.126 billion. Since the cumulative Adjusted EBITDA did not exceed the required threshold, CVR holders will not receive any payments on the CVRs and the CVRs will expire without value. The company will give formal notice to the NASDAQ Capital Market of its intention to deregister under the Securities Exchange Act of 1934 (the "Exchange Act") and delist the CVRs from the NASDAQ. The Company will also terminate its obligation to file periodic reports, such as a Form 10-K, Form 10-Q or Form 8-K, under the Exchange Act. It is expected that the CVRs will cease trading on NASDAQ on March 4, 2011. The delisting is expected to be made effective by the NASDAQ prior to the end of the first quarter 2011.

Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K for APP Pharmaceuticals, Inc. (APP)

Contingent Value Rights Issued in September 2008 Will Expire Without Value SCHAUMBURG, Ill., Feb 23, 2011 (BUSINESS WIRE) -- Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) today filed its Form 10-K for APP which provides an update on the Contingent Value Rights (CVRs) granted to APP stockholders in September 2008 in conjunction with Fresenius Kabi Pharmaceuticals Holding's acquisition of APP. Pursuant to the agreement governing the CVRs, the right to receive a payment with respect to the CVRs was contingent upon APP achieving consolidated cumulative Adjusted EBITDA in excess of $1.268 billion for the measurement period (three years ending December 31, 2010). The consolidated Adjusted EBITDA for the measurement period was $1.126 billion. Since the cumulative Adjusted EBITDA did not exceed the required threshold, CVR holders will not receive any payments on the CVRs and the CVRs will expire without value. The company will give formal notice to the NASDAQ Capital Market of its intention to deregister under the Securities Exchange Act of 1934 (the "Exchange Act") and delist the CVRs from the NASDAQ. The Company will also terminate its obligation to file periodic reports, such as a Form 10-K, Form 10-Q or Form 8-K, under the Exchange Act. It is expected that the CVRs will cease trading on NASDAQ on March 4, 2011. The delisting is expected to be made effective by the NASDAQ prior to the end of the first quarter 2011.

SCHAUMBURG, Ill., Feb 23, 2011 (BUSINESS WIRE) --
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) today filed its Form 10-K for APP which provides an update on the Contingent Value Rights (CVRs) granted to APP stockholders in September 2008 in conjunction with Fresenius Kabi Pharmaceuticals Holding's acquisition of APP. Pursuant to the agreement governing the CVRs, the right to receive a payment with respect to the CVRs was contingent upon APP achieving consolidated cumulative Adjusted EBITDA in excess of $1.268 billion for the measurement period (three years ending December 31, 2010). The consolidated Adjusted EBITDA for the measurement period was $1.126 billion. Since the cumulative Adjusted EBITDA did not exceed the required threshold, CVR holders will not receive any payments on the CVRs and the CVRs will expire without value.  

The company will give formal notice to the NASDAQ Capital Market of its intention to deregister under the Securities Exchange Act of 1934 (the "Exchange Act") and delist the CVRs from the NASDAQ. The Company will also terminate its obligation to file periodic reports, such as a Form 10-K, Form 10-Q or Form 8-K, under the Exchange Act. It is expected that the CVRs will cease trading on NASDAQ on March 4, 2011. The delisting is expected to be made effective by the NASDAQ prior to the end of the first quarter 2011.

官方網站是這樣寫著.

葉芬

昨晚投机AIB 2290,排$3.05睡觉了....三点多时起来看到价钱$3.2..要卖掉时股票行的系统发生问题....搞了整15 ...
SUNNY仔 发表于 24-2-2011 12:48 PM

咦 你不知道買賣Trading Platform要是出問題，
我們可以Call Night Desk 的嗎？

klsensgx

芬姐，我昨天买了HDY 5.38USD， 不知道是否买贵了？太冲动了！！不过我能够长期收票，你觉得他还会上到6USD 吗 ？

SUNNY仔

回复 3639# 葉芬


    嘥气啦...三更半夜CALL他们,他们就会跟你说提大堆理由...然后答案是继续卖不到,要等天亮才能解决...最后,答案出来了..原来,我的股票行是很奇怪的,当买卖有SPLIT的股票时,因为担心票数单位搞错,所以,只能买不能卖...也就为何我的买了后不能卖了...要隔了一天才可正常买卖...所以呢,今晚开市前都要流汗了..